Research programme: neuroprotectants - Cenomed BioSciences

Drug Profile

Research programme: neuroprotectants - Cenomed BioSciences

Alternative Names: Biodefense therapeutics - Cenomed BioSciences LLC; CB-2,501; Chemical defense programme - Cenomed BioSciences LLC; CM-2,501

Latest Information Update: 02 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cenomed BioSciences LLC
  • Class Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Cholinergic receptor modulators; Imidazoline receptor agonists; Serotonin receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders

Most Recent Events

  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
  • 25 Sep 2007 Cenomed BioSciences LLC establishes CRADA with the United States Army Medical Research Institute of Chemical Defense for the development of CM 2501 and related compounds as biodefense agents
  • 31 Aug 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top